Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-cancer therapeutics - AGC Biologics

Next Previous
Drug Profile

Research programme: anti-cancer therapeutics - AGC Biologics

Alternative Names: Allogeneic CAR-NK therapies - AGC Biologics; Anti-cancer therapies - AGC Biologics; Anti-tumour therapies - AGC Biologics; Autologous CAR-T therapies - AGC Biologics; CAR therapies - AGC Biologics; Chimeric antigen receptor therapies - AGC Biologics

Latest Information Update: 08 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MolMed
  • Developer AbCheck; AGC Biologics
  • Class CAR-NK cell therapies; CAR-T cell therapies; Gene therapies; Immunoglobulin Fv fragments; Immunotherapies
  • Mechanism of Action Immunomodulators; Natural killer cell replacements; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 03 Jan 2024 AbCheck has been acquired by Ampersand Biomedicines
  • 28 Jul 2022 No recent reports of development identified for research development in Cancer in Italy (Parenteral)
  • 28 Jun 2018 MolMed and AbCheck enter into a three-year Master Agreement for the development of chimeric antigen receptors targeting novel tumour antigens

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top